Press Releases
June 5, 2023
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting
May 22, 2023
NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting
May 15, 2023
NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates
April 26, 2023
NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting
March 28, 2023
NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
February 16, 2023
NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
January 18, 2023
NexImmune Announces Publication in Frontiers in Medicine Highlighting the Company’s AIM Platform to Treat Viral Diseases
November 14, 2022
NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update
October 6, 2022
NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)
September 9, 2022
NexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Displaying 1 - 10 of 66